BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Institute for Bioengineering of Catalonia - ECPv6.3.5//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:Institute for Bioengineering of Catalonia X-ORIGINAL-URL:https://ibecbarcelona.eu X-WR-CALDESC:Events for Institute for Bioengineering of Catalonia REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:Europe/Madrid BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20210328T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20211031T010000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=Europe/Madrid:20210205T100000 DTEND;TZID=Europe/Madrid:20210205T120000 DTSTAMP:20240328T152255 CREATED:20210107T101425Z LAST-MODIFIED:20210203T120455Z UID:80728-1612519200-1612526400@ibecbarcelona.eu SUMMARY:Online IBEC Seminar: Jordi Alcaraz DESCRIPTION:Improving lung cancer management by reengineering tumor-associated fibroblasts\nJordi Alcaraz\, UB facultat de Medicina & IBEC Associated Researcher \nLung cancer is the leading cause of cancer death due in part to subtoptimal patient responses to current therapies\, which have been largely designed to targeting cancer cell abnormalities. However\, there is a paradigm shift in cancer research that considers tumors as abnormal organs\, thereby acknowledging the key contribution to tumor progression provided by fibroblasts and other non-cancerous stromal cells that shape the tumor mechanical and biochemical ecosystem. \nOur group pioneered the study of tumor-associated fibroblasts (TAFs) in lung cancer in Spain in collaboration with oncologists at the Hospital Clínic. I will provide an overview of our efforts in unveiling how TAFs contribute to tumor progression in major lung cancer subtypes and in identifying how can we target such contributions with new therapeutic strategies\, including the development of novel preclinical models. Moreover\, I will describe our efforts to define novel TAF-related prognostic and/or diagnostic biomarkers. Part of this work is carried out in collaboration with pharmaceutical companies. I will also briefly summarize ongoing collaborations with IBEC groups in these topics. \nThis seminar will take place online at the GoToMeeting platform \nKnow more about Jordi Alcaraz’s research here \n\nShare this...FacebookPinterestTwitterLinkedin URL:https://ibecbarcelona.eu/event/online-ibec-seminar-jordi-alcaraz/ CATEGORIES:IBEC Seminar END:VEVENT END:VCALENDAR